Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGAL, KIM-1 and IL-18 for prediction of outcome in contrast-induced acute kidney injury and reassessment of statin intervention
ChiCTR-IPD-17010596Phase 4Recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of atorvastatin in contrast-induced nephropathy (CIN) (2 arms), sponsored by Ningbo No. 2 Hospital. Primary endpoints: Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1 and 2 more. Started Jul 2015; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR-IPD-17010596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPD-17010596.